HHS & Healthcare Contracts Intelligence — June 23, 2026

Only $2.8 million of the $141.3 million contract value has been outlayed (2% execution rate), signaling early-stage milestone-based funding and high performance risk for this small, foreign-owned disadvantaged business.

Leidos’ cost-plus-fixed-fee delivery order expires August 2024, and with no announced modification or option exercise data, the $30.4 million annual revenue stream faces renewal uncertainty within two months.

START2 GROUP’s $141.3M BARDA contract has only $2.8M outlayed through early 2024, indicating milestone-based payments and potential delays in biotechnology R&D deliverables. Company scalability as a foreign-owned small business is unproven for this scale.

Leidos’ $121.5M NIH/NCI award expires August 2024. Future NIH budget allocations for NIAID VRC research are subject to Congressional appropriations, and any continuing resolution could delay follow-on awards.

The entire digest consists of just two contracts from two HHS subagencies (BARDA and NIH/NCI), both in health R&D. No defense diversification exposes sector-specific risk from civilian budget prioritization shifts.

Both BARDA and NIH are prioritizing biodefense and vaccine R&D, creating sustained demand for specialized R&D services. START2 GROUP’s contract (through 2031) represents a long-term pipeline for investors in small-cap government biotech contractors.

Leidos’ competitive win under full and open competition for NIH health R&D demonstrates cross-agency capability. This could translate into similar civilian health contracts or expanded biodefense work under DOD’s Chemical and Biological Defense Program.

Both contracts—$141.3M BARDA biotech R&D and $121.5M NIH NIAID vaccine research—demonstrate HHS’s continued commitment to biodefense and health R&D, even as broader federal budgets face continuing resolution risk.

{"entity"=>"START2 GROUP, INC.", "reason"=>"Minimal outlays ($2.8M of $141.3M) on a seven-year contract suggest high execution risk. Successful milestone achievement could trigger significant additional funding, but delays would indicate program underperformance.", "trigger"=>"Quarterly BARDA progress reports or any contract modification indicating milestone delays"}

{"entity"=>"Leidos Holdings, Inc. (LDOS)", "reason"=>"The $121.5M NIH contract expires August 2024. A follow-on award or option exercise would confirm sustained NIH revenue; failure to renew would signal competitive loss or budget shift.", "trigger"=>"August 2024 contract end date; any NIH solicitation for NIAID VRC research support"}